Oramed Pharmaceutical Inc. Technology
Oramed is a contemporary pharmaceutical company that is mainly focused into developing new cutting-edge medicinal diabetic drugs that have not been in existence before. Similar to other pharmaceutical companies, technology is a key factor in the success such companies. In an exclusive interview on www.wallst.net with Nadav Kidron, Oramed’s CEO, he was quoted describing Oramed Pharmaceuticals Inc. as “an Israeli company focused on the development of oral delivery solutions based on proprietary technology” (PR Newswire Association LLC, 2007). Kidron’s comment demonstrates the value of technology to Oramed causing the company to patent its technology and product.
Lately Oramed focused on the development of a new diabetic drug called ORMD0801. This product, in a form of a gel capsule, can be consumed orally. ORMD0801 in turn, plays a role in eliminating the need for insulin delivery by the means of self-injecting and constant painful testing of insulin blood levels. In order to accomplish this function, Oramed will need sophisticated technology and certainly top-notch high-tech equipment. Therefore, Oramed has to in an ongoing basis to secure “in-licensing and other means of obtaining additional technologies to complement and/or expand its product portfolio” (The New York Times, 2012).
Oramed’s emerging ORMD0801 delivery is a technology in its-self. It advances the ability of the body to absorb peptides and proteins through the intestinal track wall without creating any changes to the active ingredients of the drug (Oramed, 2009). This was possible by introducing a substitute “drug delivery system” (Oramed Pharmaceuticals Inc., 2010). This delivery system will successfully deliver the drug to ...
... middle of paper ...
...012/03/20/idUS125396+20-Mar-2012+BW20120320
PR Newswire Association LLC. (2007). Exclusive Interview With Oramed Pharmaceuticals Inc. CEO, Nadav Kidron on www.Wallst.Net. PR Newswire. ProQuest Newsstand. http://proquest.umi.com/pqdlink?vinst=PROD&fmt=3&startpage=-1&vname=PQD&RQT=309&did=1256371181&scaling=FULL&vtype=PQD&rqt=309&TS=1333335886&clientId=20655
PR Newswire Association LLC. (2009). Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award. PR Newswire. http://proquest.umi.com.ezproxy.liberty.edu:2048/pqdlink?vinst=PROD&fmt=3&startpage=1&vname=PQD&RQT=309&did=1844533951&scaling=FULL&vtype=PQD&rqt=309&TS=1333049930&clientId=20655
The New York Times. (2012). Business Day. Retrieved from NY Times.com: http://topics.nytimes.com/top/news/business/companies/oramed-pharmaceuticals-inc/index.html
Spikoff, Martin. Controversy Continues to Surround Generic Insulin. 16 April 2008. 9 October 2009 .
Insulin is by far the most influential discovery in Canadian and world history. In Canada in 2008/2009 there were 2.4 million people living with diabetes and there are many more today. With out the discovery of insulin many people would not be able to live full lives. However, the discovery of insulin was not just an accomplishment Fredrick Banting and his colleagues had developed in the 1920s, it was a product of timing and luck on Banting’s part and the idea that he took from others was the product that changed the century.
...ll help the company in selling generic drugs and provide affordable medications to its customer base.
Being presented with the problems in the implementation of the SAP ERP system, it is evident that Novartis Pharmaceuticals requires a comprehensive action plan that resolves key issues and the underlying problem. Refer to Exhibit A for a graphical representation of the action plan.
candidate for a new designed drug, I am going to use a special computer program called
Size and stability: Liquid formulation can be bulky, difficult to transport and store.1 During storage under the stated conditions, it’s necessary that oral solutions are not subject to precipitation, fast sedimentation, caking or formation of lump.2 They have poor stability compare to solid dosage form formulation due to hydrolysis.1 Therefore, it’s important to optimize the active ingredient stability in liquid formulation including those prepared from powder or granules.2
Threat of new entrants is relatively high. Companies forming alliances are potential rivals. Even if earlier such company was not considered to be a threat, after merging with some research and development company or forming alliance with another pharmaceutical company it would become a rival to Eli Lilly. The threat is however weakened by significant research and development costs necessary to successfully enter the business. Eli Lilly’s focus on a relatively narrow market of sedatives and antidepressants weakens the threat of new entrants, but other products that form lesser part of company’s sales such as insulin and others are exposed to high threat of new entrants. The need of obtaining certificates and licenses also weakens the threat of new entrants. Discussed above leads to the conclusion that threat of new entrants is medium.
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
They are missing out on opportunities that exist externally. It is time for the mindset of the company to evolve and understand that not all great ideas will be developed internally. In order to jump back to being the leading pharmaceutical company, they will have to open their doors to external pharmaceutical innovation.
Scherer, A. (2012) ‘M&A in Big Pharma: Holy Grail or Buying Time’, Contract Pharma, 21 Mar [Online]. Available at: http://www.contractpharma.com/contents/view_experts-opinion/2012-03-21/ma-in-big-pharma/#sthash.NnrBSo3O.dpuf (Accessed at: 15 December 2013)
Since its humble beginning as a small drugstore, Merck has placed a large amount of importance on improving the health and well-being of its customers. As drug patents expire and genetic forms of their top products become available, Merck’s strategy is to do the unexpected; instead of raising the price of their older products in favor of patent protected new drugs, Merck focuses on reducing their cost in order to better compete with their generic counterparts. Additionally, Merck’s plan for growth now encompasses a much more aggressive pursuit of new drugs in their pipeline through extensive research. Merck became the second largest health care company in the world after the merger with Schering-Plough in 2009 and has contributed great discoveries like the first cervical cancer vaccine and great resources like the Merck Manuals which are utilized as a source of information to doctors, scientists and consumers worldwide .
Over the years the company has survived by focusing on its internal development in addition to a series of mergers, acquisitions, and corporate restructurings. Being a pharmaceutical company, the entire population is impacted: patients, physicians, employees, hospitals, and investors are some of the most important stakeholders. We first began our analysis of Novartis by evaluating the company’s strategic direction. Novartis’ mission statement is to care and to cure. They are a company that wants to discover, develop, and successfully market innovative products to prevent and cure disease, to ease suffering, and to enhance the quality of life.
Imagine not being able to have a snack or candy whenever you want to in a day. Many people have to watch what they eat, especially diabetics because of lack of insulin in their bodies. They have to watch their sugar intake daily and also keep up with insulin shots. Diabetes is a life long disease which isn’t easy to have without new technological advancements. The rapid growth of technology has made health care more successful, specifically in the advancements for the cure and treatments of diabetes.
For commodity generic drugs, Teva has an opportunity to expand its core business into emerging markets, but there it will have to face institutional voids because such markets are driven by physicians and both physician and other people are not aware about the effectiveness of generic drugs. To cope with the challenge of institutional voids Teva have to look for some competent small pharmaceutical firms for acquisition and some big firms for the joint venture. For changing the perceptions of people and physicians, Teva will require to run marketing campaigns and direct approaches to physicians to develop a market for their products.
When two companies decide to combine forces and become one bigger, richer mega company, it is called merging. This process forms a new company, combining the money and ideas of what used to be two different entities into one. This, however, is not the only thing that results from merging two different companies, and since we will be discussing the merging of two companies in the pharmaceutical industry, the impact will be incredible. Of course, the merging of two companies will not only have positive impacts but it will have many negative side effects as well. Furthermore, depending on the size of the merging companies and the goals of the people leading these companies there will always be contradictions according to the long-term goals or short-term goals depending on what both parties’ interests are. Our company, Verduga Inc. is contemplating to merge with Coronado-Salinas Inc., so before we rush into such a merger we must contemplate the positive and negative aspects of such a move. When it comes to mergers there are always many possible positive and negative impacts due to the effects of merging; these effects more widely impact the fields on research and development, on employment and management, stocks and shareholders, monopolization, and ingenuity.